Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Coherus Oncology, Inc. (CHRS) had Normalized Pre-Tax Income of $-44.86M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$10.25M |
|
$297.77M |
|
$3.40M |
|
$6.86M |
|
$55.74M |
|
$-45.49M |
|
$0.62M |
|
$-44.86M |
|
|
Normalized Pre-Tax Income |
$-44.86M |
$-44.86M |
|
$-44.86M |
|
$297.77M |
|
$-44.86M |
|
$-45.49M |
|
$-44.47M |
|
116.08M |
|
116.08M |
|
$2.57 |
|
$2.57 |
|
| Balance Sheet Financials | |
$380.20M |
|
$1.91M |
|
$59.26M |
|
$439.46M |
|
$263.63M |
|
$36.87M |
|
$56.01M |
|
$319.64M |
|
$119.83M |
|
$67.52M |
|
$119.83M |
|
116.22M |
|
| Cash Flow Statement Financials | |
$-72.46M |
|
$445.15M |
|
$-281.79M |
|
$126.25M |
|
$217.16M |
|
$90.91M |
|
$10.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.44 |
|
-- |
|
-- |
|
0.24 |
|
0.31 |
|
66.89% |
|
-443.59% |
|
-443.59% |
|
-- |
|
-437.51% |
|
2903.91% |
|
$-72.46M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
0.75 |
|
0.09 |
|
1050.08 |
|
-37.44% |
|
-66.45% |
|
-10.21% |
|
-28.63% |
|
$1.03 |
|
$-0.62 |
|
$-0.62 |
|